What Is an HPV Reflex Test If You Have ASCUS?

An HPV reflex test is an automatic follow-up test for human papillomavirus that the lab runs on the same cervical sample already collected during your Pap smear, triggered when your Pap result comes back as ASCUS. No second appointment or additional swab is needed. The word “reflex” simply means the test is performed in response to a specific finding, without a separate order from your clinician. The purpose is straightforward: ASCUS is an ambiguous result, and the HPV test helps sort out whether the cell changes on your Pap are driven by a virus that could, over time, lead to cervical precancer, or whether they reflect something harmless like inflammation or irritation.

What ASCUS Actually Means

ASCUS stands for atypical squamous cells of undetermined significance. In plain language, the person reading your Pap slide saw cells that looked a little off but not clearly abnormal enough to call a precancerous lesion. The “undetermined significance” part is key: the lab is saying it genuinely cannot tell, from looking at the cells alone, whether the changes matter or not.¹ Many things can make cells look slightly abnormal under a microscope: a yeast infection, bacterial vaginosis, recent intercourse, vaginal dryness, or just the normal turnover of cervical tissue. One older study found that among women whose ASCUS Pap results were followed up, about 70% of those who turned out not to have any real lesion had inflammation, tissue repair changes, or immature cell patterns that mimicked atypia.²

ASCUS is one of the most common abnormal Pap results, and the vast majority of the time it does not mean cancer. But a meaningful fraction of ASCUS cases do conceal an underlying precancerous change that would benefit from closer monitoring. That uncertainty is exactly why the reflex HPV test exists.

How the Reflex Test Works in Practice

Modern cervical screening almost always uses liquid-based collection. Instead of smearing cells directly onto a glass slide the old-fashioned way, the clinician rinses the sampling brush into a small vial of preservative fluid. The lab draws a portion of that fluid to prepare the Pap slide, and the rest sits in the vial. If the Pap comes back as ASCUS, the lab can go back to the leftover fluid and run an HPV DNA or mRNA test on it without needing you to come in again.³ This is why it is called “reflex” testing: the lab reflexively performs the second test using the sample already on hand.

Most reflex tests look specifically for high-risk HPV types, the strains most strongly linked to cervical cancer. There are roughly a dozen high-risk types, with HPV 16 and HPV 18 being the best-known. Some labs use DNA-based detection (identifying the virus’s genetic material), while others use mRNA-based assays that detect viral activity rather than mere presence.⁴ Both approaches aim at the same clinical question: is a cancer-associated HPV strain present?

What Happens After the Result

The reflex HPV test splits ASCUS results into two groups with very different risk profiles, and your next steps depend entirely on which group you land in.

If the HPV test is negative, your risk of having an underlying precancerous lesion is very low, similar to someone whose Pap was completely normal. Current guidelines generally recommend returning to routine screening rather than rushing to further procedures. A follow-up HPV test at one year may be suggested depending on your age and screening history, but the key message is reassurance: you likely do not need a colposcopy or biopsy.⁵

If the HPV test is positive, the immediate risk of a serious precancer is still relatively modest, around 4 to 5%, but it is high enough to warrant a closer look. Current risk-based management guidelines recommend colposcopy, a procedure in which a clinician examines the cervix under magnification and may take small tissue samples. If colposcopy does not find a significant lesion, the typical plan is to return for follow-up testing in about a year rather than go straight to treatment.⁶

Why Reflex HPV Testing Beat the Alternatives

Before reflex HPV testing became standard, the main options for handling ASCUS were to repeat the Pap in a few months, send everyone straight to colposcopy, or simply ignore the result and return to routine screening. Each had drawbacks. Repeating the Pap meant extra visits and lingering uncertainty, and many women did not come back for the follow-up. Sending everyone for colposcopy was effective at catching precancers but meant subjecting a large number of women to an unnecessary and sometimes uncomfortable procedure.

The landmark ASCUS-LSIL Triage Study, often referred to as ALTS, compared these strategies head-to-head. For women with ASCUS, HPV triage proved as sensitive as sending everyone to colposcopy while cutting colposcopy referrals roughly in half.⁷ That finding essentially settled the debate: reflex HPV testing offered the best balance of catching real disease and sparing women who did not need further workup. Cost-effectiveness analyses reinforced the point, showing that HPV DNA testing after ASCUS was both cheaper and more effective than repeat Pap smears.⁸

The Gray Zone Problem and Lab Agreement

One reason the HPV reflex test is so valuable is that ASCUS itself is inherently subjective. It sits in a gray zone between clearly normal and clearly abnormal, and pathologists frequently disagree about it. In the ALTS trial, when a quality-control reviewer re-read Pap slides originally called ASCUS, the reviewer agreed with the ASCUS classification only about 43% of the time; most of the disagreements involved downgrading the result to something less concerning.⁹

That level of disagreement extends to HPV-positive rates among different pathologists reading ASCUS slides. A study of five pathologists at the same lab found that their HPV-positive rates for ASCUS diagnoses ranged from 38% to 67%, a spread wide enough to meaningfully affect which patients got referred on for further evaluation and which were told to come back later.¹⁰ The HPV test itself is objective, either the virus is there or it is not, which helps compensate for the inherent subjectivity in reading Pap slides.

Does Age Change the Picture?

HPV is extremely common in younger sexually active people, so a positive HPV result in someone in her early twenties does not carry the same implications as it does in someone in her forties. Most HPV infections in younger women are transient and clear on their own within a year or two. For this reason, screening guidelines for women aged 21 to 24 have historically favored repeat Pap testing at 12 months rather than immediate colposcopy after an HPV-positive ASCUS result. The thinking is that intervening too aggressively in this age group risks treating infections that would have resolved without help.

That said, there is some evidence suggesting the risk of underlying precancer in young HPV-positive women with ASCUS is not necessarily lower than in older women. One study of Korean women found that among HPV-positive ASCUS cases, those aged 21 to 24 actually had a higher rate of significant precancerous changes than women aged 30 to 65.¹¹ A separate analysis of reflex HPV testing across age groups found that while HPV positivity rates dropped with age, the proportion of significant precancers detected among HPV-positive women was similar across age groups, ranging from roughly 9% to 23%.¹² The bottom line is that age matters for how likely you are to test HPV-positive in the first place, but once you are positive, the need for follow-up is real regardless of age.

At the other end of the age spectrum, postmenopausal women present a different challenge. Declining estrogen levels cause vaginal and cervical tissue to thin and become atrophic, and those changes can mimic ASCUS on a Pap smear. In some cases, a short course of local estrogen therapy can help the pathologist distinguish between atrophy-related cell changes and genuine precancerous abnormalities, potentially avoiding unnecessary colposcopy.¹³

HPV Reflex Testing During Pregnancy

If you are pregnant and your Pap comes back as ASCUS, reflex HPV testing still applies, but the management timeline shifts. The concern is not that HPV or a precancerous lesion will harm the pregnancy itself, but rather that certain follow-up procedures, particularly cervical biopsies, are best delayed until after delivery when possible. Canadian guidelines recommend that pregnant patients who are HPV-positive with ASCUS or low-grade cytology should have HPV-based screening repeated about three months after giving birth rather than proceeding immediately to colposcopy.¹⁴ In general, postponing colposcopy in pregnant women with minor Pap abnormalities until after delivery is now considered acceptable.¹⁵ The rationale is that cervical precancers progress slowly, and the few months between diagnosis and the postpartum period are unlikely to make a clinical difference for low-grade findings.

The Emotional Side of Reflex Testing

Something that gets lost in clinical discussions of reflex testing is how it feels to receive these results. For many women, getting an ASCUS result is already confusing and anxiety-provoking. Research consistently finds that most women do not understand what their abnormal screening results mean, do not know what a colposcopy is before being referred for one, and experience significant anxiety in the gap between learning their results and having any follow-up procedure.¹⁶

Being told that you are also HPV-positive adds another layer. A prospective study found that women who tested HPV-positive after an abnormal Pap had significantly higher anxiety and cancer-related worry at the time they received their results compared to women who tested HPV-negative.¹⁷ HPV carries additional stigma because it is sexually transmitted, which can bring up feelings of shame or worry about partner relationships even though the infection is extremely common and usually harmless. A separate study confirmed that HPV-positive women with ASCUS reported higher trait anxiety and worse psychosocial scores than HPV-negative women.¹⁸ The encouraging finding from both studies is that for most women, anxiety levels dropped substantially within about six months, especially once follow-up testing provided clearer answers.

If you are navigating this experience, it helps to know that the reflex test is not delivering a cancer diagnosis. It is sorting you into a risk category so that the right amount of follow-up can be applied. Most women with HPV-positive ASCUS will not have a precancerous lesion, and among those who do, the vast majority are caught at stages that are highly treatable.

How HPV Vaccination Is Changing ASCUS Management

As more women enter the screening population having been vaccinated against HPV, the landscape of ASCUS and reflex testing is shifting. Vaccination dramatically reduces infections with HPV 16 and 18, the two types responsible for the largest share of cervical precancers. A population-based study found that among women vaccinated before age 17, the predictive value of a low-grade cytology result for underlying precancer dropped by about 44% compared to unvaccinated women.¹⁹ In practical terms, this means that as vaccination rates rise, a larger share of ASCUS results in vaccinated women will reflect benign changes rather than HPV-driven precancer, which could affect how screening algorithms are calibrated in the future.

Long-term follow-up data from a randomized screening trial showed that HPV 16 contributed the greatest proportion of ASCUS risk in the population, reinforcing why vaccination against this type has such an outsized impact on the screening landscape.²⁰ For now, vaccinated women still follow the same screening and reflex-testing protocols as unvaccinated women. But as the vaccinated population grows and data accumulates, guidelines may eventually be adjusted.

Newer Triage Methods on the Horizon

Reflex HPV DNA testing has been the workhorse for ASCUS triage for over two decades, but researchers have been looking for ways to further refine it. The core limitation of HPV DNA testing is that it tells you the virus is present but not whether it is actively doing anything harmful. Most HPV infections are transient, especially in younger women, so a positive HPV DNA result can sometimes trigger follow-up for infections that would have cleared on their own.

One approach gaining traction is p16/Ki-67 dual staining, a lab test that looks for two proteins whose simultaneous presence in a cervical cell strongly suggests the virus is actively driving abnormal cell growth rather than just passively sitting there. A study evaluating this approach found that using p16/Ki-67 to triage HPV-positive women achieved similar sensitivity to standard Pap cytology triage for detecting precancer, around 92%, while improving specificity from about 49% to 61%.²¹ That improvement in specificity matters because it means fewer women without precancer would be sent for colposcopy, reducing unnecessary procedures and the anxiety that comes with them. HPV genotyping and methylation testing are also being investigated as triage strategies.²²

mRNA-based HPV tests, which detect active viral gene expression rather than just viral DNA, represent another refinement. In one comparison study, an mRNA assay was the most sensitive triage test for ASCUS, though it traded some specificity for that sensitivity gain.²³ None of these newer methods have replaced standard reflex HPV DNA testing in routine practice yet, but they represent the direction the field is heading: more precise tools that better distinguish transient infections from the ones that actually need intervention.